8 results on '"De Hosson, S"'
Number of results to display per page
Search Results
2. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
- Author
-
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group, Pulmonary medicine, CCA - Cancer Treatment and quality of life, Peters, S, Stahel, Ra, Dafni, U, Aix, Sp, Massutí, B, Gautschi, O, Coate, L, López Martín, A, Van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Noguera, Jg, Curioni Fontecedro, A, Rauch, D, Mark, Mt, Cuffe, S, Biesma, B, Van Henten, Am, Vidal, Ój, Sanchez, Rp, Villa Guzmán, Jc, Martin, Rc, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, Fortunato, De Hosson, S, Pieterman, R, Groen, Hj, Van Den Berg, Pm, Zielinski, Cc, Kuruvilla, Yc, Gasca Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, Ef, and EMPHASIS lung collaborative, Group
- Subjects
Oncology ,Male ,Lung Neoplasms ,medicine.medical_treatment ,Docetaxel ,NSCLC ,THERAPY ,Squamous ,Cohort Studies ,RETROSPECTIVE ANALYSIS ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,3RD-LINE ,Antineoplastic Combined Chemotherapy Protocols ,VeriStrat ,030212 general & internal medicine ,Erlotinib Hydrochloride ,ETOP ,Prognosis ,Survival Rate ,Erlotinib ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,Taxoids ,Veristrat ,2ND-LINE TREATMENT ,medicine.drug ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,03 medical and health sciences ,Internal medicine ,Multicenter trial ,medicine ,TYROSINE KINASE INHIBITORS ,Journal Article ,Humans ,Lung cancer ,COMBINATION ,Survival rate ,neoplasms ,METAANALYSIS ,Aged ,Neoplasm Staging ,Platinum ,Chemotherapy ,business.industry ,medicine.disease ,respiratory tract diseases ,business ,GROWTH-FACTOR RECEPTOR ,Follow-Up Studies - Abstract
Introduction: Docetaxel and erlotinib are registered second line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial.Methods: EMPHASIS-lung was a randomized phase III multicenter trial exploring the differential effect of second line erlotinib versus docetaxel on progression-free survival (PFS) in VeriStrat good versus VeriStrat poor patients with squamous cell NSCLC.Results: A total of 80 patients were randomized, with 72.5% categorized as VeriStrat good. Patient characteristics were balanced between VeriStrat status and treatment groups. The median PFS times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 4.1 and 1.6 months, respectively, versus 1.9 and 2.1 months, respectively, in the VeriStrat poor cohort. The median overall survival (OS) times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 7.8 and 8.4 months, respectively, and 4.4 and 5.2 months, respectively, in the VeriStrat poor cohort. An additional exploratory analysis was performed; in it, 47 patients from the squamous cell subgroup of PROSE were included in a combined analysis, contributing with 45 PFS and 41 OS events.Conclusions: The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p=0.24 for PFS and 0.45 for OS, stratified by study). (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
- Published
- 2016
- Full Text
- View/download PDF
3. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
- Author
-
Peters, S. Stahel, R.A. Dafni, U. Ponce Aix, S. Massutí, B. Gautschi, O. Coate, L. López Martín, A. van Heemst, R. Berghmans, T. Meldgaard, P. Cobo Dols, M. Garde Noguera, J. Curioni-Fontecedro, A. Rauch, D. Mark, M.T. Cuffe, S. Biesma, B. van Henten, A.M.J. Juan Vidal, Ó. Palmero Sanchez, R. Villa Guzmán, J.C. Collado Martin, R. Peralta, S. Insa, A. Summers, Y. Láng, I. Horgan, A. Ciardiello, F. de Hosson, S. Pieterman, R. Groen, H.J.M. van den Berg, P.M. Zielinski, C.C. Chittazhathu Kurian Kuruvilla, Y. Gasca-Ruchti, A. Kassapian, M. Novello, S. Torri, V. Tsourti, Z. Gregorc, V. Smit, E.F. EMPHASIS-lung Collaborative Group
- Subjects
neoplasms ,respiratory tract diseases - Abstract
Introduction Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial. Methods EMPHASIS-lung was a randomized phase III multicenter trial exploring the differential effect of second-line erlotinib versus docetaxel on progression-free survival (PFS) in VeriStrat good versus VeriStrat poor patients with squamous cell NSCLC. Results A total of 80 patients were randomized, with 72.5% categorized as VeriStrat good. Patient characteristics were balanced between VeriStrat status and treatment groups. The median PFS times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 4.1 and 1.6 months, respectively, versus 1.9 and 2.1 months, respectively, in the VeriStrat poor cohort. The median overall survival (OS) times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 7.8 and 8.4 months, respectively, and 4.4 and 5.2 months, respectively, in the VeriStrat poor cohort. An additional exploratory analysis was performed; in it, 47 patients from the squamous cell subgroup of PROSE were included in a combined analysis, contributing with 45 PFS and 41 OS events. Conclusions The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p = 0.24 for PFS and 0.45 for OS, stratified by study). © 2017 International Association for the Study of Lung Cancer
- Published
- 2017
4. Dyspneu e causa ignota (e.c.i.)
- Author
-
Majoor, C. J., Heijdra, Y., De Hosson, S. M., Tip, M. J., Van Putten, J. W. G., Van der Werf, T. S., Amsterdam institute for Infection and Immunity, and Pulmonology
- Published
- 2010
5. Adult HERMES: Criteria for accreditation of ers european training centres in adult respiratory medicine
- Author
-
Loddenkemper, R., Severin, T., Mitchell, S., Belevskiy, A., Chuchalin, A., de Hosson, S., di Maria, G., Hartl, S., Horvath, I., Leroyer, C., Noel, J., Nybo, B., Phillips, G., Stevenson, R., Zach, M., and Palange, Paolo
- Published
- 2010
6. Adult HERMES: criteria for accreditation of ERS European training centres in adult medicine
- Author
-
Loddenkemper, R, primary, Severin, T, additional, Mitchell, S, additional, Belevskiy, A, additional, Chuchalin, A, additional, de Hosson, S, additional, Di Maria, G, additional, Hartl, S, additional, Horvath, I, additional, Leroyer, C, additional, Noel, J-L, additional, Nybo, B, additional, Phillips, G, additional, Stevenson, R, additional, Zach, M, additional, and Palange, P, additional
- Published
- 2010
- Full Text
- View/download PDF
7. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
- Author
-
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, and Smit EF
- Subjects
- Aged, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell pathology, Cohort Studies, Docetaxel, Erlotinib Hydrochloride administration & dosage, Female, Follow-Up Studies, Humans, Lung Neoplasms pathology, Male, Neoplasm Staging, Platinum administration & dosage, Prognosis, Survival Rate, Taxoids administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Squamous Cell drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat poor. EMPHASIS-lung aimed at exploring this predictive effect in patients with squamous cell NSCLC. The trial closed prematurely because of low accrual and results from other trials. Our analysis includes an exploratory combined analysis with results from the PROSE trial., Methods: EMPHASIS-lung was a randomized phase III multicenter trial exploring the differential effect of second-line erlotinib versus docetaxel on progression-free survival (PFS) in VeriStrat good versus VeriStrat poor patients with squamous cell NSCLC., Results: A total of 80 patients were randomized, with 72.5% categorized as VeriStrat good. Patient characteristics were balanced between VeriStrat status and treatment groups. The median PFS times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 4.1 and 1.6 months, respectively, versus 1.9 and 2.1 months, respectively, in the VeriStrat poor cohort. The median overall survival (OS) times with docetaxel and erlotinib treatment in the VeriStrat good cohort were 7.8 and 8.4 months, respectively, and 4.4 and 5.2 months, respectively, in the VeriStrat poor cohort. An additional exploratory analysis was performed; in it, 47 patients from the squamous cell subgroup of PROSE were included in a combined analysis, contributing with 45 PFS and 41 OS events., Conclusions: The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p = 0.24 for PFS and 0.45 for OS, stratified by study)., (Copyright © 2017 International Association for the Study of Lung Cancer. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
8. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians.
- Author
-
Janssen DJ, de Hosson SM, bij de Vaate E, Mooren KJ, and Baas AA
- Subjects
- Adult, Aged, Cross-Sectional Studies, Dyspnea etiology, Female, Health Care Surveys, Humans, Male, Middle Aged, Netherlands, Patient Acceptance of Health Care, Ambulatory Care methods, Analgesics, Opioid therapeutic use, Attitude of Health Personnel, Dyspnea drug therapy, Palliative Care methods, Practice Patterns, Physicians' statistics & numerical data, Pulmonary Disease, Chronic Obstructive complications
- Abstract
Dyspnea is the most frequently reported symptom of outpatients with advanced chronic obstructive pulmonary disease (COPD). Opioids are an effective treatment for dyspnea. Nevertheless, the prescription of opioids to patients with advanced COPD seems limited. The aims of this study are to explore the attitudes of Dutch chest physicians toward prescription of opioids for refractory dyspnea to outpatients with advanced COPD and to investigate the barriers experienced by chest physicians toward opioid prescription in these patients. All chest physicians (n = 492) and residents in respiratory medicine (n = 158) in the Netherlands were invited by e-mail to complete an online survey. A total of 146 physicians (response rate 22.5%) completed the online survey. Fifty percent of the physicians reported to prescribe opioids for refractory dyspnea in 20% or less of their outpatients with advanced COPD and 18.5% reported never to prescribe opioids in these patients. The most frequently reported barriers toward prescription of opioids were resistance of the patient, fear of possible adverse effects, and fear of respiratory depression. To conclude, Dutch chest physicians and residents in respiratory medicine rarely prescribe opioids for refractory dyspnea to outpatients with advanced COPD. This reluctance is caused by perceived resistance of the patient and fear of adverse effects, including respiratory adverse effects., (© The Author(s) 2015.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.